Research programme: diabetes therapy - Roche/Yissum
Latest Information Update: 29 Oct 2009
At a glance
- Originator Yissum Research Development Company
- Developer Roche; Yissum Research Development Company
- Mechanism of Action Cannabinoid receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 23 Oct 2009 Investigation in Type-2 diabetes mellitus in Israel (unspecified route)
- 23 Oct 2009 Investigation in Type-1 diabetes mellitus in Israel (unspecified route)